STOK
Stoke Therapeutics Inc.
$30.04
-$1.66(-5.24%)
62
Overall
60
Value
83
Tech
44
Quality
Market Cap
$1.73B
Volume
1.34M
52W Range
$5.35 - $38.69
Target Price
$28.22
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | -- | -- | -- | $12.4M | $8.8M | $36.6M | ||
| Total Revenue | -- | -- | -- | $12.4M | $8.8M | $36.6M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | -- | -- | -- | $12.4M | $8.8M | $36.6M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $-35.7M | $53.0M | $86.1M | $116.8M | $123.6M | $137.9M | ||
| Research & Development | $23.8M | $32.2M | $54.2M | $77.8M | $82.2M | $89.1M | ||
| Research Expense | $23.8M | $32.2M | $54.2M | $77.8M | $82.2M | $89.1M | ||
| Selling, General & Administrative | $11.9M | $20.8M | $31.9M | $38.9M | $41.3M | $48.8M | ||
| General & Administrative Expenses | $11.9M | $20.8M | $31.9M | $38.9M | $41.3M | $48.8M | ||
| Salaries & Wages | $-1.9M | -- | -- | -- | $25.3M | $27.5M | ||
| Depreciation & Amortization | $-450.0K | $900.0K | $1.0M | $1.5M | $2.5M | $2.2M | ||
| Depreciation & Amortization | $-450.0K | $900.0K | $1.0M | $1.5M | $2.5M | $2.2M | ||
| Other Operating Expenses | $-35.7M | $53.0M | -- | -- | $123.6M | $137.9M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-35.7M | $-53.0M | $-86.1M | $-104.4M | $-114.8M | $-101.4M | ||
| EBITDA | $-31.9M | $-52.2M | $-85.1M | $-102.8M | $-102.5M | $-88.4M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | $49.0K | $26.0K | ||
| Intinc | $3.4M | $700.0K | $120.0K | $3.1M | $9.9M | $12.6M | ||
| Net Non-Operating Interest Income/Expense | $3.4M | $700.0K | $120.0K | $3.1M | $9.9M | $12.6M | ||
| Other Income/Expense | $-2.0K | $-101.0K | $-140.0K | $167.0K | $-166.0K | $247.0K | ||
| Other Special Charges | $2.0K | $101.0K | $140.0K | $167.0K | $166.0K | $-247.0K | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-32.3M | $-53.0M | $-86.1M | $-104.4M | $-104.7M | $-89.0M | ||
| Pre-Tax Income | $-32.3M | $-52.2M | $-85.8M | $-101.1M | $-104.7M | $-89.0M | ||
| NET INCOME | ||||||||
| Net Income | $-32.3M | $-52.2M | $-85.8M | $-101.1M | $-104.7M | $-89.0M | ||
| Net Income (Continuing Operations) | $-32.3M | $-52.2M | $-85.8M | $-101.1M | $-104.7M | $-89.0M | ||
| Net Income (Discontinued Operations) | $-32.3M | $-52.2M | $-85.8M | $-101.1M | $-104.7M | $-89.0M | ||
| Net Income (Common Stockholders) | $-32.3M | $-52.2M | $-85.8M | $-101.1M | $-104.7M | $-89.0M | ||
| Normalized Income | -- | -- | $-67.8M | -- | -- | $-88.1M | ||
| TOTALS | ||||||||
| Total Expenses | $-35.7M | $53.0M | $86.1M | $116.8M | $123.6M | $137.9M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $18.0M | $33.5M | $36.7M | $38.9M | $44.0M | $54.0M | ||
| Average Shares Outstanding (Diluted) | $18.0M | $33.5M | -- | $38.9M | $44.0M | $54.0M | ||
| Shares Outstanding | $32.9M | $36.7M | $37.4M | $44.1M | $46.3M | $54.1M | ||
| Basic EPS | -- | $-1.56 | $-2.34 | $-2.6 | $-2.38 | $-1.65 | ||
| Basic EPS (Continuing Operations) | -- | $-1.56 | $-2.34 | $-2.6 | $-2.38 | $-1.65 | ||
| Diluted EPS | $-1.8 | $-1.56 | $-2.34 | $-2.6 | $-2.38 | $-1.65 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.6 | $-2.38 | $-1.65 | ||
| OTHER METRICS | ||||||||
| Other Gand A | $11.9M | $20.8M | $31.9M | $38.9M | $41.3M | $48.8M | ||
| Rent And Landing Fees | $11.9M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STOK | $30.04 | -5.2% | 1.34M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |